With PolyPeptide Group, SIX welcomes another company from the life sciences sector, further expanding its strong peer group and strengthening its position as Europe’s leading exchange for life sciences companies.
The issued share capital of PolyPeptide comprises of 33,125,001 registered shares, whereas 3,125,000 newly issued registered shares together with existing 8,396,740 registered shares were offered in the IPO. At an issue price of CHF 64.00 per registered share, the placement volume was CHF 737 million (excluding over-allotment option). In addition, the selling shareholder has granted an overallotment option of up to 1,728,261 existing shares.
Peter Wilden, Chairman PolyPeptide, says: “With its focused strategy since its beginnings in 1952, PolyPeptide has become a leader in its field and today manufactures around one-half of all currently approved peptide drug substances. While today’s listing at SIX marks an important milestone in the history of our company, it should also be seen as a strong expression of our ambition to drive innovation for the benefit of patients around the world. My thanks go to the PolyPeptide team and everyone who helped make this possible.”
Jos Dijsselhof, CEO SIX, says: “I am delighted to welcome PolyPeptide, an international company with Swedish roots and a long lasting history, on our exchange. PolyPeptide’s IPO confirms that SIX has been and continues to be highly attractive for international companies and that the appeal of its life sciences sector and ecosystem extends far beyond the borders of Switzerland.”
The Swiss Stock Exchange represents more than a third of the European life sciences market capitalization. The sector also accounts for around 35% of the total market capitalization of the Swiss Stock Exchange (as of April 2021).
For more information about PolyPeptide, please see www.polypeptide.com
Further information on the life sciences sector at SIX is available here.